Today’s biologic medicines, like antibodies and recombinant proteins, are all derived from genetic materials. The DNA (gene) known to produce a therapeutic protein is inserted into a host cell, such as a bacteria or mammalian cells. The host cells then replicate and make the therapeutic protein. This is achieved using recombinant DNA technology developed in the late 1970’s and 1980’s. Biologic therapeutics are still made using this core technology.

A new era has arrived, whereby Klotho Neuroscience’s platform technology can introduce the genetic material directly into human cells in the body, and the patient then becomes the “factory” for protein production inside their body. This approach is called gene therapy.

Klotho Neurosciences licensed exclusive rights to develop and commercialize a key product platform technology – a human gene and protein therapy utilizing an important gene referred to as α-Klotho.
α-Klotho was named after the Greek goddess Klotho (or Clotho), the regulator of life and aging. Thus, α-Klotho is referred to as the “anti-aging” gene and protein because there is striking evidence of α-Klotho inhibiting or reversing age-related pathologies. This includes inhibiting or stopping memory loss, cognition, and other manifestations of dementia, as well as affecting neuromuscular diseases, arteriosclerosis, osteoporosis, dermal (skin) aging, sarcopenia (muscle wasting), kidney function, and certain cancers.